menu
    • menu
    [{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"DUSA Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc."},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"DUSA Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc."},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"DUSA Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Oncology","graph2":"Phase II","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc."},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"DUSA Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Oncology","graph2":"Undisclosed","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc."},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Dermatology","graph2":"Phase II","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"DUSA Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dental and Oral Health","graph2":"Phase IV","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc."},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"DUSA Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ DUSA Pharmaceuticals, Inc."},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Edward Maytin","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Edward Maytin","highestDevelopmentStatusID":"1","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Edward Maytin"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Goldman, Butterwick, Fitzpatrick and Groff","highestDevelopmentStatusID":"1","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Goldman, Butterwick, Fitzpatrick and Groff"}]

    Find Clinical Drug Pipeline Developments & Deals by DUSA Pharmaceuticals, Inc.

    Menu

    DUSA Pharmaceuticals, Inc.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Medical Dermatology Specialists

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients

                            Details : 5-aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Skin Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2017

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Medical Dermatology Specialists

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Rhode Island Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ

                            Details : 5-aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Carcinoma, Squamous Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 19, 2017

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Rhode Island Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

                            Details : Aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Keratosis, Actinic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 18, 2017

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face

                            Details : Aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2015

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)

                            Details : Aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2015

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetirizine Dihydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Goldman, Butterwick, Fitzpatrick and Groff

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Ass...

                            Details : Cetirizine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Keratosis, Actinic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 22, 2015

                            Lead Product(s) : Cetirizine Dihydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Goldman, Butterwick, Fitzpatrick and Groff

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase IV

                            Recipient : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis

                            Details : Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cheilitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 07, 2015

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase IV

                            Recipient : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

                            Details : Aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 02, 2014

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (A...

                            Details : Aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 15, 2014

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            DUSA Pharmaceuticals, Inc.

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : Edward Maytin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome

                            Details : 5-aminolevulinic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Basal Cell Nevus Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2014

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : Edward Maytin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth